5-hydroxytryptophan has been researched along with Dyskinesia, Drug-Induced in 7 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
Dyskinesia, Drug-Induced: Abnormal movements, including HYPERKINESIS; HYPOKINESIA; TREMOR; and DYSTONIA, associated with the use of certain medications or drugs. Muscles of the face, trunk, neck, and extremities are most commonly affected. Tardive dyskinesia refers to abnormal hyperkinetic movements of the muscles of the face, tongue, and neck associated with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS). (Adams et al., Principles of Neurology, 6th ed, p1199)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Progress in the treatment of action myoclonus is especially noteworthy and has led to the implication of serotonin deficit in the pathophysiology of this syndrome." | 1.26 | New approaches in the management of hyperkinetic movement disorders. ( Fahn, S, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Meloni, M | 1 |
| Puligheddu, M | 1 |
| Sanna, F | 1 |
| Cannas, A | 1 |
| Farris, R | 1 |
| Tronci, E | 2 |
| Figorilli, M | 1 |
| Defazio, G | 1 |
| Carta, M | 2 |
| Lisci, C | 1 |
| Stancampiano, R | 1 |
| Fidalgo, C | 1 |
| Collu, M | 1 |
| Devoto, P | 1 |
| Sedel, F | 1 |
| Ribeiro, MJ | 1 |
| Remy, P | 1 |
| Blau, N | 1 |
| Saudubray, JM | 1 |
| Agid, Y | 1 |
| Nasrallah, HA | 2 |
| Smith, RE | 2 |
| Dunner, FJ | 2 |
| McCalley-Whitters, M | 2 |
| Maj, J | 1 |
| Rogóz, Z | 1 |
| Dlaboga, D | 1 |
| Dziedzicka-Wasylewska, M | 1 |
| Fahn, S | 1 |
3 trials available for 5-hydroxytryptophan and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding.
Topics: 5-Hydroxytryptophan; Animals; Antiparkinson Agents; Cross-Over Studies; Dose-Response Relationship, | 2020 |
Serotonin precursor effects in tardive dyskinesia.
Topics: 5-Hydroxytryptophan; Adult; Aged; Carbidopa; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle | 1982 |
Pharmacologic probes of neurotransmitter systems in tardive dyskinesia: implications for clinical management.
Topics: 5-Hydroxytryptophan; Adult; Aged; Choline; Clinical Trials as Topic; Dihydroxyphenylalanine; Dopamin | 1986 |
4 other studies available for 5-hydroxytryptophan and Dyskinesia, Drug-Induced
| Article | Year |
|---|---|
5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Topics: 5-Hydroxytryptophan; Adrenergic Agents; Animals; Caudate Nucleus; Disease Models, Animal; Dopamine; | 2013 |
Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia.
Topics: 5-Hydroxytryptophan; Adult; Antidepressive Agents, Second-Generation; Dopamine Agents; Drug Combinat | 2006 |
Pharmacological effects of milnacipran, a new antidepressant, given repeatedly on the alpha1-adrenergic and serotonergic 5-HT2A systems.
Topics: 5-Hydroxytryptophan; Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Amphetamin | 2000 |
New approaches in the management of hyperkinetic movement disorders.
Topics: 5-Hydroxytryptophan; Carbidopa; Chorea; Dyskinesia, Drug-Induced; Humans; Movement Disorders; Myoclo | 1977 |